A GLP-1 for Heart Risk: What the Cardiovascular Indication Means

Most people take these medications for weight and think of them as weight medications. For a specific group, that is not the whole label.

What the indication actually says

The Wegovy prescribing information includes an indication to reduce the risk of major adverse cardiovascular events, defined there as cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight.

Read the qualifier carefully, because it is doing the work. This is not an indication for people who are worried about their heart, or who have risk factors, or who have a family history. It is for people who already have diagnosed cardiovascular disease.

If that is not you, this indication is not about you, and nothing below should be read as a reason to expect a cardiac benefit from your treatment.

The trial behind it

The evidence is the SELECT trial, published in the New England Journal of Medicine in 2023.

It enrolled 17,604 people aged 45 or older who had established cardiovascular disease and a BMI of 27 or above, and who did not have diabetes. Mean follow-up was just under 40 months.

The main composite outcome occurred in 6.5% of people on semaglutide and 8.0% on placebo, a hazard ratio of 0.80. In plain terms, roughly a fifth fewer of those events over about three years.

Two honest notes on that figure. The absolute difference is 1.5 percentage points, which is a real but modest shift in individual terms and a substantial one across a population. And discontinuation because of side effects was considerably higher on the medication, 16.6% against 8.2%, so a meaningful number of people did not stay on it.

The part that surprised people

The benefit did not appear to be explained entirely by how much weight participants lost. That has been the subject of a great deal of analysis and debate since, and it is not fully settled.

What it means practically is modest but worth knowing: if you are in this group, the case for treatment does not rest solely on the number on the scale. Someone whose weight loss is unremarkable may still be getting something, which is a different conversation from the usual one about whether treatment is working.

It also means the reverse. Losing a great deal of weight is not evidence that your cardiovascular risk has fallen by any particular amount.

Where this actually matters to you: coverage

This is the most useful practical consequence and it is the one people miss.

An approved indication is a different thing to argue with an insurer about than an off-label or weight-only request. If you have established cardiovascular disease and either obesity or overweight, you may fit a labeled indication that has nothing to do with weight-management coverage, which is frequently excluded.

Worth raising with your prescriber specifically: whether you meet the criteria for that indication, and whether a prior authorization framed around it is stronger than one framed around weight. Plans differ and this is not a guarantee. But people are routinely denied on weight-management grounds while fitting a cardiovascular indication that nobody thought to cite.

Consider this scenario: someone who had a heart attack three years ago and has a BMI of 31 is turned down because their plan excludes weight-loss drugs. Their denial letter and their appeal both discuss weight. Nobody involved looks at whether they fit the cardiovascular indication instead, which is a different question with a different answer.

This is not a substitute for cardiac care

Worth saying plainly, because the framing invites confusion.

A medication with a risk-reduction indication sits alongside cardiac treatment, not in place of it. If you have cardiovascular disease you are presumably on other medications, and none of them become optional because of this.

Do not stop or reduce anything on the basis of starting a GLP-1. And make sure whoever manages your heart care knows you are taking it, because they are watching a whole picture and this belongs in it. That is doubly true because weight loss changes how some cardiac and blood pressure medications behave, and those may need adjusting as you go.

What to do with this

If you have established cardiovascular disease: raise the indication by name with your prescriber and with your cardiologist. Ask whether you fit it, and if you do, whether that is the framing your coverage request should use.

If you have risk factors but no diagnosed disease: this indication does not apply to you. Whether treatment is appropriate is still a real conversation, just not this one.

If you are already taking one of these medications for weight: nothing changes about your treatment. It is worth knowing whether you happen to fit a second indication, mainly for coverage purposes.

Whoever manages your heart needs to be in the loop. Not as a formality. Our guide on getting the most out of your GLP-1 treatment covers what ongoing monitoring should look like, and with cardiovascular disease the monitoring matters more than the medication list.

The tolerability question is not incidental

Given that one in six participants stopped because of side effects, how you tolerate the medication is part of whether you get any benefit at all. A treatment you cannot stay on does not reduce anyone’s risk.

That makes the unglamorous parts more important rather than less: starting low, moving up slowly, and treating side effects as something to manage rather than endure. Our guide on the semaglutide starting dose covers the early progression, and our guide on when to increase your tirzepatide dose covers why the timing of each step is a decision rather than a schedule.

The short version

Semaglutide carries an approved indication to reduce major cardiovascular events in adults who already have established cardiovascular disease plus obesity or overweight. The trial behind it found roughly a fifth fewer of those events over about three years, a 1.5 point absolute difference, with notably more people stopping for side effects. The benefit was not clearly explained by weight loss alone. If you fit that description, the most useful thing here is that it gives you a different and often stronger coverage argument than a weight-management request. And it sits alongside your cardiac care rather than replacing any of it.

If you want a provider who will look at which indication you actually fit before submitting a coverage request, TrimRx includes ongoing provider access alongside treatment.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.